The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Open accessAbstract
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. METHODS: We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. RESULTS: Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. CONCLUSIONS: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of hyperlipidemic patients with monoclonal antibodies that target and inactivate PCSK9 results in increased hepatic LDLR expression and significantly reduced plasma LDL-C40,41.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with PCSK9 inhibitors reduces LDL-C by approximately − 60% [75–79].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“ASO silencing of Rnf130 resulted in a 50% decrease in LDL-C, a change comparable to inhibiting PCSK940,41, further supporting that RNF130 is a significant regulator of LDLR and LDL-C levels.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 579
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationRaal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Self-citationAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
Self-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Self-citationGiugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Self-citation
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 722
The Newest Frontier in Cholesterol Management; PSCK 9
Dashwood, A. M. (2014) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000127 · Cited by 1
PCSK9-Inhibitoren bei Hypercholesterinämie
Parhofer, K. G. (2016) · Herz · doi:10.1007/s00059-016-4416-6 · Cited by 1
Lipid-Lowering Therapy and Apheresis: Indications and Outcomes
Moriarty, P. M., & McCalley, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_12 · Cited by 1
Korszerű lipidcsökkentő kezelés
Paragh, G., & Karádi, I. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30505 · Cited by 1
Application of Genomics to the Study of Human Growth Disorders
Guo, M. H., & Dauber, A. N. (2016) · Translational bioinformatics · doi:10.1007/978-981-10-1104-7_18 · Cited by 1
Evaluation of an Evidence-based Medicine Educational Program for Pharmacists and Pharmacy Students
Shimizu, T., Ueda, M., Toyoyama, M., Ohmori, S., & Takagaki, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00190-5 · Cited by 1
Medikamentöse Senkung des LDL-Cholesterins
Barthelmes, J., & Sudano, I. (2017) · Praxis · doi:10.1024/1661-8157/a002759 · Cited by 1
Drugs That Affect Lipid Metabolism
Beckett, R. D., Wilhite, A. L., Robinson, N., & Rosene, A. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.005 · Cited by 1
Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence
Stamerra, C. A., Giosia, P. D., Giorgini, P., Feo, M. D., Grassi, D., Ferri, C., & Sahebkar, A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24199 · Cited by 1
What has the GLAGOV clinical study shown?
Murín, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.066 · Cited by 1
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_14 · Cited by 1
Self-citationAbdelfattah, O., Sayed, A., Al-Refaei, A., Abdeldayem, J., Moustafa, K., Elias, N., & Saleh, Y. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070008 · Cited by 1
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
Jin, Z., He, T., Peng, L. J., Wu, X., Fan, D., Chen, M., Fan, Y., Guo, Y., Lu, Z., & Wang, H. (2023) · Current Medical Science · doi:10.1007/s11596-023-2791-9 · Cited by 1
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
Shnaider, K. O., Maksimov, М. L., Baranova, V. A., & Nekipelova, A. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-366 · Cited by 1
Echevarría, A. B., García-Díaz, J. D. D., Caixàs, A., Plana, N., Corral, M. Á. R., Bridges, I. M., Dhalwani, N. N., Menchen, S. G., & Ray, K. K. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.04.003 · Cited by 1
Dovizio, M., Nugnes, M., Iacolare, B., NAPPI, C., Saragoni, S., Andretta, M., Barbieri, A., Bartolini, F., CHINELLATO, G., Cillo, M., et al. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06626-2 · Cited by 1
Update on PCSK9 Inhibitors and New Therapies
Stein, E. A., & Raal, F. J. (2016) · US Endocrinology · doi:10.17925/use.2016.12.01.18 · Cited by 1
Self-citationMueller, Z. T., Craddock, K. E., Pitlick, J. M., & Crannage, A. J. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516653970 · Cited by 1
The art and science of the drug discovery pipeline
Loging, W. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9780511989421.002 · Cited by 1
1. Hypercholesterolemia: a disease of the brain
Singh, R. B., Niaz, M. A., Takahashi, T., Meester, F. D., Wilczyńska, A., Saboo, B., Maheshwari, A., Cornelissen, G., Singh, J., & Télessy, I. G. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-821-6_1 · Cited by 1
Studying genetic resilience to improve human health
Cirulli, E. T., & Ginsburg, G. (2016) · Oral Diseases · doi:10.1111/odi.12567 · Cited by 1
Cardiovascularis prevenció – 2016
Vértes, A., & Szabados, E. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30577 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Parhofer, K. G. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0233-7 · Cited by 1
Sá, F. M., Ruivo, C., Santos, L. G., Antunes, A., Soares, F. C., Baptista, J., & Morais, J. (2018) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2018.02.016 · Cited by 1
Progressão ultrarrápida de doença coronária ou placa instável não detetada?
Sá, F. M., Ruivo, C., Santos, L. G., Antunes, A., Soares, F. C., Baptista, J., & Morais, J. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.04.005 · Cited by 1
Lipid Disorders and Familial Hypercholesterolaemia
Pottle, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_57 · Cited by 1
Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
May, H. T., Muhlestein, J. B., Ma, Y., López, J. A. G., Coll, B., & Nelson, J. R. (2019) · Cardiology and Therapy · doi:10.1007/s40119-019-0133-6 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
New Trends Approved in Management of Dyslipidaemia
Aboshahba, A. (2019) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2019.14.555894 · Cited by 1
Efficacy of Evolocumab in Patients with Hypercholesterolemia
Jin, X. S., Kim, M. H., Cho, Y., Park, J.-S., Song, K., & Yuan, S. L. (2020) · Kosin Medical Journal · doi:10.7180/kmj.2020.35.2.125 · Cited by 1
The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests
Superko, H. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_15 · Cited by 1
Kunimura, A., Yano, Y., Hisamatsu, T., Torii, S., Kondo, K., Kadota, A., Fujiyoshi, A., Okamura, T., Watanabe, Y., Shiino, A., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15723 · Cited by 1
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
PCSK9 inhibitors for LDL lowering
Walsh, J. P. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.02.001 · Cited by 1
Saving Lives: Children’s and Adults’
Shulman, S. T. (2014) · Pediatric Annals · doi:10.3928/00904481-20140417-01 · Cited by 1
Xiao, J., Zhang, S., Shu, H., Chen, X., Zhou, L., Shang, K., Qin, C., Xu, W., & Tian, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2038721/v1 · Cited by 1
Wang, J. D. J., Teo, A. Y. T., Xiao, B., Chao, Y., Zhou, Z. D., Tan, B. J.-W., Chan, L.-L., Rosalie, E., & Tan, E.-K. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00568-y
New and Emerging Therapies for Hyperlipidemia
Wong, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_15
Cuende, J. I., Lahoz, C., Armario, P., García-Alegría, J., Ena, J., de Casasola, G. G., & Mostaza, J. M. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.07.005
Terapia con anticuerpos monoclonales en Cardiología y Medicina Interna
Adams-Sánchez, C. D., & Tobón-García, G. J. (2016) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.02.003
Lepor, N. E., Contreras, L., Desai, C., & Kereiakes, D. J. (2015) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0773corr
Sultan, A. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30092-x
Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK9 Inhibitors.
Roncevic, S. M., Gobić, D., Jurjević, T. Z., Miculinić, Ž. R., & Zaputović, L. (2016) · Cardiologia Croatica · doi:10.15836/ccar.2016.330
Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid‑lowering therapy
Wójcik, C. (2016) · Reviews in Health Care · doi:10.7175/rhc.v7i1.1263
(2016) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2016.07.00235
Iyengar, S. (2016) · Journal of Clinical and Preventive Cardiology · doi:10.4103/2250-3528.192689
New options in the treatment of hypercholesterolaemia
Soška, V., & Kyselák, O. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.002
Ein Fall für die Lipoprotein-Apherese
Bernhardt, W. M., & Röseler, T. (2017) · CardioVasc · doi:10.1007/s15027-017-1072-6
Wills, B., Rincón, A., Montenegro, A. C., & Sandoval, A. F. B. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.11.002
Genome-based cholesterol drug boosts heart health
Ledford, H. K. (2017) · Nature · doi:10.1038/nature.2017.21656
Evolocumab: rising momentum as novel antidyslipidemic drug
Mehani, R., Shukla, A. K., Yadav, V. K., & Sahu, R. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20172713
Hipercolesterolemia familiar heterocigota en manejo con anti–PCSK9
Duque, M., Gaviria, M. C., González, J., & Gallo, J. E. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.03.002
PCSK9 inhibitors – Clinical viability and practical considerations
Kandasamy, A. D. (2017) · Diabesity · doi:10.15562/diabesity.2017.39
Do PCSK9 inhibitors reduce cardiovascular events?
Kolber, M. R., Nickonchuk, T., & Turgeon, R. D. (2018) · Europe PMC (PubMed Central)
Morales-Villegas, E., & Ray, K. K. (2019) · Frontiers in cardiovascular drug discovery · doi:10.2174/9781681083995118040007
Advanced Peripheral Artery Vessel Wall Imaging and Future Directions
Loffler, A. I., & Kramer, C. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25249-6_9
Comments on the most important and recent studies involving PCSK9i
Češka, R. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.162
The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
Rengarajan, R., Tecson, K. M., & McCullough, P. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_7
Management of Homozygous Familial Hypercholesterolemia
Santos, R. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_20
GOLIATH regulates LDLR availability and plasma LDL cholesterol levelsPreprint
Clifford, B. L., Jarrett, K. E., Cheng, J., Cheng, A., Seldin, M. M., Morand, P., Lee, R. E., Jr., Baldán, Á., Vallim, T. Q. D. A., & Tarling, E. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.09.415323
PCSK9-Inhibitoren - Erfahrungen im klinischen Alltag
Kassner, U., & Hollstein, T. (2020) · CardioVasc · doi:10.1007/s15027-020-3423-y
Eficacia del tratamiento con evolocumab en pacientes con cardiopatía isquémica
Ramos-Martínez, E. G., Mayoral, L. P.-C., Hernández-Mercado, M. A., & Ramos-Martínez, J. C. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/99743
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed, Z. V., Juthani, P. V., Lee, M. L., & Desai, N. R. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_11
Faculty Opinions recommendation of Effect of alirocumab on mortality after acute coronary syndromes.
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735819386.793563697
PCSK9 as a Biomarker of Cardiovascular Disease
Ooi, T. C., & Abujrad, H. (2015) · Springer eBooks · doi:10.1007/978-94-007-7741-5_20-1
Toth, P. P. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_3
Self-citationBiller, J., & Schneck, M. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726014687.793538029
Anti-PCSK9 : nouvelle classe thérapeutique contre le mauvais cholestérol
(2014) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(14)72639-5
冠動脈疾患を有する家族性高コレステロール血症の血液中proprotein convertase subtilisin/kexin 9の意義
有, 片., 聡, 安., & 斯波真理子 (2016) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.24.2_237
Murakami, T. (2011) · Springer eBooks · doi:10.1007/springerreference_33738
Berberoğlu, Z. (2018) · EMJ Diabetes · doi:10.33590/emjdiabet/10311250
Gu, H., Huang, W., Fu, J., Liu, Y., Zhang, Y., Huang, T., Wei, X., Liu, D., Luo, W., Ma, W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2453552/v1
Use of the PCSK9 inhibitor, evolocumab, in patients with heterozygous familial hypercholesterolemia
Srinivasan, S. (2019) · MOJ Public Health · doi:10.15406/mojph.2019.08.00301
Fujino, M., & Nicholls, S. J. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e14
Feasibility and efficacy of PCSK9 inhibitors in cases of statin therapy limitation or intolerance
Shnaider, K. O., Baranova, V. A., & Maksimov, M. L. (2023) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2307-02
Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis
刘, 扬. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381742
Hasan, N. A., Kalanjati, V. P., Purwantari, K. E., Abdurachman, A., & Miftahussurur, M. (2023) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres23.1741_12.2.218
Lupachev, R. M., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2401-02
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
van den Heuvel, R. (2024) · doi:10.55788/52f78782
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Çaklılı, Ö. T., Rizzo, M., & Cesur, M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611290763240126045433
Statine: Nebenwirkungen – alternative Therapieoptionen
Makhmudova, U., & Weingärtner, O. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00669-w · Cited by 1
Koutsogianni, A. D., Barkas, F., Tellis, C. C., Tselepis, A. D., Liamis, G. L., & Liberopoulos, E. N. (2023) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1051
A Comprehensive Review and Prospects on the Impact of Lipid-Lowering Drugs on Cognitive Functions
韩, 立. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143894
Hoogeveen, R. C., & Ballantyne, C. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00014-1
Self-citationChallenges in the management of familial hypercholesterolemia: a case report
Rogozik, J. K., Grabowski, M., & Główczyńska, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1417432
PCSK9 Targeted Therapy to Lower Cholesterol and Reduce Cardiovascular Events
Abramson, B. L., & Nelson, S. M. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.114
Akash, M. S. H., & Rehman, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36312-2.00005-x
Xu, L., Lei, M., Li, L., Li, Y., Gu, C., & Zheng, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1555508
Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review
Rodrigues, L. D. S., & Bertanha, M. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2025.0005
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Secondary prevention of stroke
Markus, H. S., Pereira, A. C., & CLOUD, G. C. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198906261.003.0010
Каминный, А. И., Ломакин, Н. В., Shuvalova, Y. A., Машина, А. П., Дмитриевна, А. Е., Каминная, В. И., Чигинева, В. В., & Мясникова, Е. В. (2025) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2025.03.0003
Nishino, M., Egami, Y., Okamoto, N., Sunaga, A., & Yano, M. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02623-6
van Bruggen, F. H., Zuidema, S. U., & Luijendijk, H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26085140
Yu, M., Zhao, X., Chen, Y.-Y., Tao, X.-W., Ge, J.-B., Jin, H., & Zeng, M.-S. (2023) · Figshare · doi:10.6084/m9.figshare.23084080
Kongmalai, T., Chuanchaiyakul, N., Sripatumtong, C., Tansit, T., Srinoulprasert, Y., Klinsukon, N., & Thongtang, N. (2021) · Figshare · doi:10.6084/m9.figshare.14121509
Fischer, L. T., Hochfellner, D. A., Knoll, L., Pöttler, T., Mader, J. K., & Aberer, F. (2021) · Figshare · doi:10.6084/m9.figshare.14479997
Metadata
- Authors
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., & Stein, E. A.
- Affiliations
- University of Cape Town (ZA)
- National Institutes of Health (US)
- Midwest Institute for Clinical Research (US)
- Stellenbosch University (ZA)
- Sterling Research Group (US)
- Jacksonville Center for Clinical Research (US)
- Houston Methodist (US)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1809-1819
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155259933
- Semantic Scholar
- 8d480541d9ba40d0cf45fea465f3b42bfc2b2f19
- Cited by
- 720
- References
- 16
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 44 · 2022: 26 · 2021: 33 · 2020: 46 · 2019: 49 · 2018: 62 · 2017: 92 · 2016: 110 · 2015: 103 · 2014: 48
- FWCI
- 116.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Open University of Cape Town (University of Cape Town) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, monoclonal antibodies, atorvastatin, ezetimibe, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, treatment safety
- MeSH terms
- Atorvastatin, Ezetimibe, Proprotein Convertase 9, Adult, Aged, Antibodies, Monoclonal, Azetidines, Combined Modality Therapy, Double-Blind Method, Female, Heptanoic Acids, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Serine Endopeptidases, Least-Squares Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
